Press Release: Epiphany Biosciences Raises $36 Million Round in Private Financing

Epiphany Biosciences Raises $36 Million Round in Private Financing SAN FRANCISCO, March 15, 2007 -- Epiphany Biosciences, a new biotech company with a therapeutic focus on discovering and developing anti-infective agents, announced today the closing of a $36 million Series A financing. Wexford Capital, LLC led the financing and was joined by major investor Windsor Bay Capital, LLC and by Global Trust Ventures Management, LLC, CDIB BioScience Venture Management (CBVM) and several private investors. "We are extremely pleased to have attracted such a high-quality group of investors," said Epiphany CEO Fred Volinsky, MD. "Epiphany has assembled one of the finest virology teams in life science today, a group that includes our Chief Scientific Officer Michael Houghton, PhD, Chief Medical officer Brian Murphy, MD, MBA, co-founder Robert Gallo, MD, and Scientific Advisory Board members Drs. Roger Kornberg, Hans Wigzell, Yuan Chang, Patrick Moore, and other eminent scientists and clinicians," noted Volinsky. "The funding will enable us to advance our lead programs including our anti-viral drug candidate Valomaciclovir (EPB-348) through Phase 2b clinical trials against shingles as well as Epiphany's development of HHV-8/KSHV screening diagnostics," added David Myles, PhD, COO. Epiphany is committed to bringing life-improving therapeutics and diagnostics to patients suffering from chronic and debilitating conditions caused by infectious agents. About Epiphany Biosciences Epiphany Biosciences is focused on advancing new therapies for infectious disease. Epiphany's founding team includes a world class group of virologists as well as several Albert Lasker award winners. The founders of Epiphany Biosciences include Fred Volinsky MD, Robert Gallo MD, David Myles PhD, Barry Selick PhD, and Lee Meisel MD, JD, MPH. Epiphany is located in San Francisco, CA. Additional information on Epiphany Biosciences may be obtained at the company website www.epiphanybio.com or by contacting company representatives: Fred G. Volinsky MD, CEO 415.765.7193; David C. Myles PHD, COO 415.765.7198. CONTACT: Fred G. Volinsky MD, CEO, +1-415-765-7193, or David C. Myles PHD,COO, +1-415-765-7198, both of Epiphany Biosciences Web site: http://www.epiphanybio.com/

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.